Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New knee shot aims to ease arthritis pain without surgery

NCT ID NCT07580716

Symptom relief Sponsor: Enlivex Therapeutics Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 27, 2026 · Updated 2 times

Summary

This study tests an experimental drug called Allocetra, given as a shot into the knee joint, for people aged 64+ with moderate-to-severe knee osteoarthritis. The goal is to see if it reduces pain and improves function better than a placebo. About 270 participants will be followed for 6 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 270 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

64 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants must meet all of the inclusion criteria listed below to be eligible for the study: 1. Age 64 years or above. 2. Diagnosis of primary femorotibial knee OA. 3. Radiographic evidence of knee OA defined as Kellgren-Lawrence (KL) grade 2 or 3 in the index knee. 4. Participants who are intolerant to, or have failed to adequately respond to at least 2 OA therapies. 5. Index knee pain assessed during the screening period and following wash-out of pain medications. 6. Willingness to abstain from prohibited medications/treatments during the trial. 7. Women who are postmenopausal (≥12 months natural amenorrhea without alternative cause) or surgically sterilized (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy). 8. Male participants with partners of childbearing potential, who are not surgically sterile (vasectomy) for at least 6 months prior to randomization, must use condoms with spermicide in addition to their partner's contraception from randomization and for 90 days after last dose. Exclusion Criteria: Participants will be excluded from the study if they meet any of the following criteria: 1. Severe or end-stage osteoarthritis of the index knee. 2. Clinically significant structural abnormalities or instability of the index knee. 3. Recent major injury, surgical procedure, or intra-articular treatment in the index knee. 4. Any known history of infection or tumor of the index knee, or active infection at the intended injection site. 5. Any known history of inflammatory arthropathy or crystal-deposition disease. 6. Any severe systemic cartilage, bone, or musculoskeletal disorder that may interfere with study outcomes. 7. Clinically significant widespread pain syndromes. 8. Immunosuppressive therapy, clinically significant immunodeficiency, or active infection. 9. Body Mass Index (BMI) \>40 kg/m² 10. Use of medications that may interfere with pain assessment or study outcomes. 11. Known coagulopathy or use of anticoagulant/antiaggregant medication. 12. Significant uncontrolled systemic disease or clinically significant findings on screening laboratory tests or physical examination.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary knee osteoarthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

osteoarthritis osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary knee osteoarthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    17 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centrum Medyczne PLEJADY

    NOT_YET_RECRUITING

    Krakow, 30-363, Poland

  • DC-MED Michal Kowalski S.K. Radom

    NOT_YET_RECRUITING

    Radom, 26-610, Poland

  • DC-MED Michal Kowalski S.K. Swidnica

    RECRUITING

    Swidnica, 58-100, Poland

  • DelRicht Research @ Touro Medical Center

    RECRUITING

    New Orleans, Louisiana, 70115, United States

  • Etg Justmed

    NOT_YET_RECRUITING

    Warsaw, 01-696, Poland

  • Etg Warszawa

    RECRUITING

    Warsaw, 02-677, Poland

  • Future Medical Research

    RECRUITING

    Longwood, Florida, 32750, United States

  • Medyczne Centrum Hetmańska

    RECRUITING

    Poznan, 60-218, Poland

  • Migre Polskie Centrum

    NOT_YET_RECRUITING

    Wroclaw, 52-210, Poland

  • NZOZ Bif-Med. s.c

    NOT_YET_RECRUITING

    Bytom, 41-902, Poland

  • Oakland Medical Research

    RECRUITING

    Troy, Michigan, 48085, United States

  • Reumedika sp. z o.o.

    NOT_YET_RECRUITING

    Poznan, 60-446, Poland

  • Sanos Clinic Gandrup

    RECRUITING

    Gandrup, 9362, Denmark

  • Sanos Clinic Herlev

    RECRUITING

    Herlev, 2730, Denmark

  • Sanos Clinic Vejle

    RECRUITING

    Vejle, 7100, Denmark

  • South Florida Research Phase I-IV

    RECRUITING

    Miami, Florida, 33166, United States

  • Vita Longa Sp. z o.o.

    NOT_YET_RECRUITING

    Katowice, 40-748, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.